<DOC>
	<DOCNO>NCT01092702</DOCNO>
	<brief_summary>The goal proposal explore potential effectiveness varenicline treat tobacco dependence among recover alcoholic smoker , group , high risk tobacco-caused morbidity mortality . In open-label phase II clinical trial , propose enroll 32 recover alcoholic smoker motivate stop smoking . After initial titration varenicline week 1 , 32 subject receive total 2 mg/day varenicline 12 week . In addition receiving varenicline , subject receive brief behavioral counsel standard intervention visit participation study .</brief_summary>
	<brief_title>Varenicline For Smokers In Recovery From Alcohol Dependence</brief_title>
	<detailed_description>This open-label , phase II clinical trial . All subject screen study eligibility providing informed consent . During clinic screen visit subject inform study , study inform consent sign subject staff member , series screening test conduct screen criterion review . Once enrolled study , subject return face face clinic visit weekly first 4 week ( visit 3-6 ) biweekly last 8 week ( visit 7-10 ) . Target quit day day visit 3 ( week 1 visit ) . During first week varenicline start dose 0.5 mg daily day 1-3 ; 0.5 mg twice daily day 4-7 . Target quit date set day 8 . Varenicline continue week 2-12 dose 1 mg twice daily . Subjects return weekly 4 week bi-weekly remain 8 week . The study end-date Week 12 , also end-of-treatment date .</detailed_description>
	<mesh_term>Tobacco Use Disorder</mesh_term>
	<mesh_term>Varenicline</mesh_term>
	<criteria>1 . Male nonpregnant female cigarette smoker ; 18yearsofage old reporting smoking least average 10 cigarette per day past year . 2 . A history alcohol dependence base DSM IV criterion assess Alcohol Dependence Scale physician investigator 3 . A minimum 6 month abstinence alcohol use assessed physician investigator 4 . Subject must able complete study visit 5 . Subject must general good health determine medical history , physical exam physician investigator 6 . Subject must provide write informed consent participate study . 1 . Current treatment another investigational drug . 2 . Current use ( within past 30 day ) nicotine replacement therapy , bupropion , rimonabant , varenicline , nortriptyline , clonidine , medication know effective treating tobacco dependence . 3 . Subject current ( past 30 day ) major depressive disorder history another psychiatric disorder psychosis bipolar disorder . 4 . Current ( past 6 month ) drug abuse corroborate Drug Abuse Screening Test ( DAST20 ) physician interview . 5 . Regular use tobacco product ( i.e . pipe , cigar , smokeless tobacco ) within past 30 day . 6 . Females pregnant , lactate likely become pregnant trial willing use acceptable form contraception medication phase . For woman childbearing potential , pregnancy test perform prior entry study end medication phase . 7 . A history major cardiovascular event past 3 month include unstable angina , acute MI coronary angioplasty . 8 . Known allergy varenicline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Tobacco Dependence</keyword>
	<keyword>Smoking</keyword>
	<keyword>Tobacco Cessation</keyword>
</DOC>